-
Data further highlights the potential to inform treatment selection for antibody-drug conjugates and other targeted therapies across breast, lung, and gastroesophageal cancers
-
Targets revealed from a single 1 mL plasma sample include B7H4, CEACAM5, CLDN18, EGFR, HER2, HER3, MET, NECTIN4, and TROP2
-
To date, this platform has uncovered therapeutically effective disease biology across 15 cancer types.
BOSTON, April 10, 2024 (Globe Newswire) — Precede Biosciences, a company impacting the development and use of precision medicine with its first-in-class, comprehensive epigenomic liquid biopsy platform, today announced that it was recognized by the American Medical Association in 2024. We have shared 3 scientific poster presentations. Cancer Research (AACR) Annual Meeting.
“The data presented at AACR 2024 further strengthens the body of evidence supporting our platform's unique ability to provide genome-wide insights into therapeutic targets, pathways, and activation status of resistance mechanisms, all from a simple blood draw. ” said Carl Barrett. , Chief Scientific Officer at Precede Bio. “As such, we have a significant opportunity to better inform patient selection and enable expanded indications for many promising drugs that address these goals and pathways using our platform. I am.”
“Our study highlights the need for new approaches to profile the biology of gastroesophageal adenocarcinoma, an aggressive disease in which patients progress rapidly,” said the Massachusetts General Hospital researchers. said Samuel Klempner, MD, medical oncologist and lead author of the summary on gastroesophageal cancer. – Esophageal cancer. “Precede Bio’s liquid biopsy platform has the potential to be an important advancement in enabling informed treatment decisions and personalized patient care throughout the entire spectrum of this difficult-to-treat cancer. ”
Precede Bio's poster for AACR 2024 can be found in the presentation section of the company's website and is linked directly below.
About Precede Biosciences
Precede Biosciences is breaking down barriers to precision medicine by redefining what can be learned from a simple blood draw. Understanding the fundamental biology behind disease at any given time allows researchers and clinicians to better deliver medicines to the right patients, both in drug development and clinical practice. Precede Bio aims to improve the success rate of drug development and help build a future where all patients receive rapid, minimally invasive diagnosis and treatment that is accurate to the biology of their disease. Precede Bio's platform is available to drug developers and academic researchers. If you would like to learn more please visit: www.precede.bio or follow us X/Twitter and linkedin.
Media contact:
Brooke Shenkin
brook@scientpr.com
Donnell M. Gregory
media@precede.bio